CST, 81691T, Phospho-c-Kit (Tyr721) (F2Z4X) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying Kit (Tyr721) phosphate. Validated for Western Blotting. Available in 2 sizes. Highly specific and rigorously validated in-house, Phospho-c-Kit (Tyr721) (F2Z4X) Rabbit Monoclonal Antibody (CST #81691) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity Phospho-c-Kit (Tyr721) (F2Z4X) Rabbit Monoclonal Antibody recognizes endogenous levels of c-Kit protein only when phosphorylated at Tyr721. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr721 of human c-Kit protein. Background c-Kit is a member of the subfamily of receptor tyrosine kinases that includes PDGF, CSF-1, and FLT3/flk-2 receptors (1,2). It plays a critical role in activation and growth in a number of cell types, including hematopoietic stem cells, mast cells, melanocytes, and germ cells (3). Upon binding with its stem cell factor (SCF) ligand, c-Kit undergoes dimerization/oligomerization and autophosphorylation. Activation of c-Kit results in the recruitment and tyrosine phosphorylation of downstream SH2-containing signaling components, including PLCγ, the p85 subunit of PI3 kinase, SHP2, and CrkL (4). Molecular lesions that impair the kinase activity of c-Kit are associated with a variety of developmental disorders (5), and mutations that constitutively activate c-Kit can lead to pathogenesis of mastocytosis and gastrointestinal stromal tumors (GIST) (6). Tyr719 (Tyr721 in human c-Kit, Tyr722 in rat) is located in the kinase insert region of the catalytic domain. c-Kit phosphorylated at Tyr719 binds to the p85 subunit of PI3 kinase and (7). A number of RTK inhibitors have been evaluated in the clinical space in patients with c-Kit driven tumors, beginning with imatinib in 2002 (8). More recently, improved outcomes have been observed with repretinib in patients with advanced, imatinib-resistant GIST (9,10). Alternate Names C-Kit; c-Kit protooncogene; CD117; ckit; KIT; KIT proto-oncogene, receptor tyrosine kinase; Mast/stem cell growth factor receptor; Mast/stem cell growth factor receptor Kit; MASTC; p145 c-kit; PBT; Piebald trait protein; Proto-oncogene c-Kit; proto-oncogene tyrosine-protein kinase Kit; SCFR; soluble KIT variant 1; Tyrosine-protein kinase Kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 145, 120 Source/Isotype: Rabbit IgG